JW Life Science

KSC:234080 · KR7234080000

PharmaceuticalsSmall

360

Medium confidence — indicative

Value57

Profit price44

EV / EBIT56

Price / Owner Earnings31

Cash yield47

Owner Earnings Yield93

Dividend Yield1

Sales & asset price49

Price/Sales55

EV / Gross Profit42

Price/Book50

Quality76

Returns on capital92

Return on Capital90

Cash Return on Capital93

Return on Equity92

Profit margins69

EBIT Margin83

Gross Profitability55

Cash backing70

Cash Conversion60

Accruals53

Owner Earnings Margin97

Growth50

Sales growth20

Profit growth37

Profit Growth30

Long-Term EPS Growth38

Owner Earnings Growth43

Reinvestment18

Price momentum49

Safety73

Debt load48

Debt serviceability62

Refinancing50

Debt Payback73

Liquidity64

Sentiment53

Analyst ratings100

Expectations trend50

Market mood6

Value Creation12/20creating some value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

JW Life Science clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

TypePublic Company

ExchangeKOSE

Founded1994

Websitejw-lifescience.co.kr

ISINKR7234080000

Last UpdateApr 2, 2026

Indices

KOSPI (South Korea)

Themes

NutraceuticalManufacturing

Description

Analysis

Quality compounder

JW Lifescience Corporation is a quality compounder: a well-run business trading at a price that reflects what it is worth.

The price is attractive. You pay 4.7× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone.

The trajectory is moderate and the balance sheet is sturdy. The company scores 12/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare JW Life Science with its peers

Redox

ASX:RDX

CountryAustralia

IndustryTrading Companies & Distributors

SizeMedium

Full Stock Analysis →

Korea United Pharm

KSC:033270

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

SD Biosensor

KSC:137310

CountrySouth Korea

IndustryHealth Care Equipment & Supplies

SizeSmall

Full Stock Analysis →

Sound Group

NAQ:SOGP

CountrySingapore

IndustryEntertainment

SizeSmall

Full Stock Analysis →

Miwon Chemicals

KSC:134380

CountrySouth Korea

IndustryChemicals

SizeSmall

Full Stock Analysis →

Kolmar

KSC:024720

CountrySouth Korea

IndustryPersonal Products

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →